Pharmaceutical

LP-184 by Starlight Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval

LP-184 is under clinical development by Starlight Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer.

Jul 6, 2024 - 04:00
LP-184 is under clinical development by Starlight Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer.
Read the original article

Tags:

Previous Article

ICTCAR-028 by Innovative Cellular Therapeutics for Hematological Tumor: Likeliho...

Next Article

Dalfampridine IR by Solaxa for Spinocerebellar Ataxia (SCA): Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

CPHI Europe: Overcoming the unique challenges with high-concentration mAbs

CPHI Europe: Overcoming the unique challenges with high...

Oct 12, 2024

AIFA’s horizon scanning 2024 predictions suggest an influx of ATMPs

AIFA’s horizon scanning 2024 predictions suggest an inf...

May 31, 2024

The fundamentals of developing parenteral drug products 

The fundamentals of developing parenteral drug products 

Nov 9, 2024